Real-World Clinical Outcomes of Sulbactam-Durlobactam Against Carbapenem-Resistant Acinetobacter baumannii with Diverse β-Lactamase Profiles: A Multicenter Study in China
{{output}}
Background: Sulbactam-durlobactam (SUL-DUR) was approved in China in 2024 for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. However, real-world clinical data-particularly in critically ill patie... ...
